Econazole 1%

There is no image.

Econazole

Method of action: Gynecological Antiinfectives And Antiseptics

Treatment option: Balanitis, Jock Itch, Candidiasis,Vaginal, Cutaneous Candidiasis, Empeines, Shingles, Pityriasis Versicolor, Athlete'S Foot

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Econazole 1%

What Type of Medicine is Econazole 1%?

Econazole 1% is a medication classified as an azole antifungal agent, used for addressing superficial infections caused by susceptible fungi and yeasts. The active component is econazole nitrate, a synthetic derivative of imidazole that functions as a broad-spectrum antimycotic. This medication works by disrupting the fungal cell wall to exert its action. This classification is shared with related compounds like clotrimazole and miconazole, placing econazole within an established family of agents used for skin mycoses. The econazole nitrate compound is a recognized pharmaceutical substance used in the management of fungal skin conditions.

The Composition and Purpose of the 1% Topical Formulation

The designation of "1%" specifies the concentration of the active ingredient, econazole nitrate, within the pharmaceutical preparation. In this concentration, each gram of the product contains 10 mg of the active substance. Econazole 1% is typically formulated as a single-ingredient product in a topical cream or topical foam for dermal application. The cream formulation is often prepared in a water-miscible base, designed to facilitate contact with the skin's surface and aid in delivering the active substance. Its therapeutic purpose is to provide antifungal efficacy directly to the site of infection. Because there is minimal systemic absorption following application, the medicine’s action is concentrated locally on the skin surface.

Regulatory References

What side effects are possible with Econazole 1%?

Econazole 1%: Possible side effects and safety information

The safety profile for Econazole 1% is documented in regulatory sources based on observed adverse reactions, primarily involving the Skin and subcutaneous tissue disorders and General disorders and administration site conditions.

Frequency-Classified Adverse Reactions

The adverse reactions are classified by regulatory authorities according to their observed frequency:

Classification	Adverse Reaction Entities
Common (≥1/100 to <1/10)	Application site burning, Pruritus (Itching)
Uncommon (≥1/1,000 to <1/100)	Application site irritation, Erythema (Redness)
Frequency Not Known	Contact dermatitis, Rash, Urticaria, Hypersensitivity, Angioedema

These common local effects, such as burning and pruritus, are often related to local tolerance and may be observed at the beginning of treatment.

Serious Adverse Reactions and Safety Constraints

The official labeling notes the potential for Immune system disorders, including clinically significant but rare reactions such as Hypersensitivity and Angioedema.

Contraindication: Econazole 1% is contraindicated in individuals with a history of hypersensitivity to econazole nitrate or any component of the formulation.
Drug Interaction Note: Caution is advised in patients taking oral anticoagulants (e.g., Warfarin) as, despite minimal systemic absorption, the medicine may enhance the anticoagulant effect. This is documented as a high-level safety consideration.

Population-Specific Considerations

Specific safety statements are included for particular populations:

Pregnancy and Lactation: Due to the potential for low systemic absorption, use during the first trimester of pregnancy should be considered only if deemed essential. Caution is also advised when the medicine is administered to a nursing woman.

Overdose and Emergency Response

The official regulatory profile for Econazole 1% topical cream or foam is strictly defined by the context of exposure. Overdosage resulting from the intended topical application has not been reported to date in humans, a finding consistent with the very low systemic absorption of the active ingredient. Due to this minimal risk, the primary focus in official labeling is on the potential consequences of accidental ingestion.

Overdose Context	Documented Manifestations & Actions
Accidental Ingestion	Following accidental swallowing, official documents state that gastrointestinal symptoms, including nausea, vomiting, and diarrhoea, may occur.
Exposure to Eyes	Accidental application to the eyes requires immediate washing with clean water or saline, and medical attention must be sought if symptoms persist afterward.

When Immediate Medical Help is Required

If the product is accidentally ingested, the patient or caregiver must contact a Poison Control Center or a doctor right away. Immediate emergency medical attention is required if severe or life-threatening symptoms, such as passing out or difficulty breathing, develop.

The regulatory guidance for managing accidental ingestion is to provide symptomatic treatment, as no specific antidote is known or documented in the labeling. These actions are mandated to address the documented risks associated with the misuse of the product.

Therapeutic Uses of Econazole 1%

What Econazole 1% Treats: Main Uses and Benefits

Econazole 1% is applied across domains where additional symptomatic support is needed for symptoms related to inflammatory or irritative states. It is a medicine commonly used to help with the symptomatic management of fungal infections, and is relevant in contexts marked by increased discomfort or tension.

The medication is commonly used to help with conditions like athlete’s foot (Tinea pedis), jock itch (Tinea cruris), ringworm (Tinea corporis), and certain cutaneous candidiasis and Tinea versicolor infections. These are conditions where symptoms may intensify temporarily due to fungal overgrowth.

“The primary benefit is in providing symptomatic relief that may assist with easing the overall symptom load.”

The treatment helps address symptom clusters that may become intense or disruptive, including symptoms related to physical discomfort such as itching and burning. It supports the healing process for physical manifestations such as widespread redness (erythema) and excessive scaling. By addressing these physical changes, the treatment contributes to improved comfort during symptomatic periods and may assist with maintaining functional stability.

Quick Fact: Relief for Irritative States This medicine is applied across domains where additional symptomatic support is needed for symptoms related to inflammatory or irritative states on the skin. It is relevant for easing discomfort that commonly interferes with daily comfort, supporting patients during episodes of heightened discomfort.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Econazole 1%?

The population eligibility for Econazole 1% topical formulations is strictly defined by regulatory documents, focusing on absolute prohibitions, age restrictions, and use during maternal states.

Eligibility Scope

Classification	Eligibility Rule
Populations for whom use is contraindicated:	Individuals with known hypersensitivity to any of the ingredients in the specific formulation (e.g., the cream).
Age-related eligibility rules:	Use in the general pediatric population is not established for the cream formulation. The foam is approved for patients 12 years of age and older, with safety not established in children younger than 12.
Pregnancy and lactation eligibility status:	Pregnancy (First Trimester): Use is conditional, only if considered essential to the patient's welfare. Lactation: Caution should be exercised, as excretion in human milk is not known.

Eligibility-Context Constraints

Adults (18+ years) are generally allowed for all labeled indications. For older adults (65+ years) using the cream, clinical studies lacked sufficient data to determine if they respond differently from younger subjects. There are no formal restrictions documented based on isolated hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Econazole 1% topical preparations identify a single, clinically significant interaction domain. This interaction involves a specific class of orally administered blood-thinning medicines.

Documented Pharmacokinetic Interaction

The most important documented interaction is with coumarin anticoagulants, which include medicines such as warfarin, acenocoumarol, and dicumarol. Co-administration with topical econazole may result in the enhancement of the anticoagulant effect of the coumarin derivative. This is classified as an exposure-modifying interaction that requires specific procedural control.

Interaction-Related Procedural Constraints

The regulatory profile strictly links the relevance of this interaction to the conditions of application that can increase the amount of active substance absorbed into the body (systemic exposure). The required constraints are:

Constraint Type	Official Regulatory Condition
Interacting Substances	Coumarin Anticoagulants
Conditional Risk Factors	Application to a large body surface area, the genital area, or use under occlusion (wrapping the skin)
Mandatory Monitoring	Monitoring of International Normalized Ratio (INR) and/or prothrombin time is formally indicated for patients receiving coumarins under the conditional risk factors.

No interactions with food, alcohol, herbal products, or other medicinal product classes are explicitly documented in the official prescribing information for topical Econazole 1%.

Mechanism of Action

How Econazole 1% Works

Econazole 1% operates through a dual mechanistic approach resulting in the loss of structural integrity in susceptible fungal cells.

Blocking Ergosterol Production and Causing Fungal Cell Failure

This primary domain involves the inhibition of a fungal enzyme, lanosterol 14-alpha-demethylase ( CYP51), which is necessary for synthesizing the cell membrane component, ergosterol. Blocking this pathway leads to the depletion of ergosterol and the toxic accumulation of abnormal sterols, resulting in the loss of the fungal cell's structural and osmotic integrity; the molecular effect is classified as fungicidal.

Direct Physical Membrane Disruption

The drug's imidazole structure allows for a secondary, non-enzymatic mechanism where it physically intercalates into the fungal cell membrane. This direct interaction destabilizes the membrane's lipid bilayer, increasing its permeability and accelerating the leakage of vital intracellular components, which contributes to the extent of the cell damage and loss of viability.

Secondary Modulation of Local Tissue Response

Econazole also engages a supplementary mechanism in the surrounding host tissue. This action modulates local inflammatory mediator synthesis, including prostaglandins and leukotrienes, resulting in decreased local inflammatory pathway signaling.

Dosage and Administration Information

Econazole 1% is strictly for topical administration to the skin surface. The preparation is exclusively for external use and must not be introduced into the eyes, mouth, or internally, such as intravaginally. The medicine is supplied as a cream or foam formulation, each containing 10 mg of econazole nitrate per gram.

Administration and Dosing Regimens

Treatment frequency and duration depend on the specific condition being addressed:

Condition	Frequency	Course Duration
Tinea cruris, T. corporis, T. versicolor	Once Daily (QD)	2 Weeks
Cutaneous Candidiasis	Twice Daily (BID)	2 Weeks
Tinea pedis (Cream or Foam)	Once Daily (QD)	4 Weeks

A sufficient quantity is applied to the affected area and the immediate surrounding skin, and then gently rubbed in. If a dose is missed, it should be applied as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed application should be skipped to prevent doubling the dose.

Population-Specific and Handling Instructions

The topical foam formulation is for use in patients 12 years of age and older for interdigital Tinea pedis. Use of the cream in children younger than 12 is determined by a healthcare provider. Furthermore, the foam formulation is flammable; precautions include avoiding heat, open flame, and smoking during and immediately following the product's application. Guidelines suggest that the full course duration must be completed. If no clinical improvement is noted after the specified treatment period, the diagnosis should be re-evaluated by a healthcare professional.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Econazole 1%

Evidence for Use in Tinea Pedis (Athlete's Foot) and Cutaneous Candidiasis

Research into Tinea Pedis (athlete's foot) was primarily conducted through short-term, randomized controlled trials (RCTs). These studies were designed to explore how this topical formulation compares to an inactive preparation (a vehicle) over a defined period. Researchers primarily focused on a measurement called the Complete Cure Rate, which required that a patient be free of the fungus (mycological clearance) and simultaneously demonstrate complete scoring of symptom resolution, such as redness, scaling, and itching, at the end of the study. This research was applied in studies examining patient-reported experiences related to physical discomfort.

The evidence base for Cutaneous Candidiasis, a condition characterized by fluctuating or episodic manifestations caused by Candida yeast, consists of earlier RCTs and is relevant in trials assessing short-term symptom patterns. Research examined the visible signs of infection and whether the yeast organism was cleared from the skin, which researchers define as mycological cure. Studies reported how symptoms evolved in the observed populations over the typical treatment course of a few weeks.

Evidence for Tinea Corporis, Tinea Cruris, and Tinea Versicolor

Econazole 1% was evaluated in research exploring Tinea Corporis (ringworm) and Tinea Cruris (jock itch), which are conditions involving periods of heightened symptoms. The evidence base for these uses includes older RCTs and is also discussed within systematic reviews that examine the azole antifungal class as a whole. Studies monitored outcomes related to physical discomfort, such as the changes in itching and redness, and the measured clearance of the dermatophyte organism. Findings help contextualize how patients reported their experience during the short study period.

For Tinea Versicolor, studies explored short-term symptom changes, including the clearance of the Malassezia furfur organism, and monitored outcomes related to scaling and pruritus. Research highlights changes measured during the study period. Research also observed responses over defined time intervals to assess changes in skin pigmentation following the end of treatment.

What is Still Uncertain About Econazole 1%

Research provides context but not individual predictions.

Key research gaps include:

Long-term outcomes are not well characterized. The follow-up durations were limited, providing insufficient data to fully understand the risk of the infection returning over many months.
Comparative evidence is lacking. While the medicine was studied against an inactive vehicle (placebo) in some key trials, detailed comparative evidence against all other modern, active topical antifungals is not consistently available in the public domain.
Evidence quality varies across studies. For some indications, the research base relies on studies noted by systematic reviews to have an unclear risk of bias due to age or design.
Subgroup findings are uncertain. Data for certain groups, such as younger children for the cream formulation or individuals with specific comorbid conditions, remain insufficient for a robust summary. The results apply only to the populations studied.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Econazole 1% (FAQ)

Q: What is Econazole 1% mainly used to treat?

Econazole 1% is officially indicated for the topical treatment of specific fungal and yeast infections of the skin. This includes conditions like athlete’s foot (tinea pedis), jock itch (tinea cruris), ringworm (tinea corporis), and cutaneous candidiasis. The medicine is classified as an azole antifungal agent.

Q: How long does it take for Econazole 1% to start showing improvement?

Official information indicates that the majority of patients experience an early relief of symptoms after beginning treatment. While the full course duration is fixed, observable clinical improvement may be seen relatively soon after treatment is started.

Q: Can Econazole 1% cause the skin to turn red or peel?

Yes, redness (erythema) and peeling (desquamation) of the treated skin are reported as adverse reactions in official safety documents. If a reaction occurs that suggests chemical irritation or sensitivity, regulatory guidelines indicate that the medication is to be discontinued.

Q: Is the cream formulation of Econazole 1% different from the powder or spray?

Econazole 1% is officially available as a topical cream and a topical foam. These specific formulations have different approved age restrictions (the foam is approved for patients 12 and older) and may be indicated for different conditions. Powder or spray forms of the medication are not described in the main regulatory labels.

Q: How long should I expect to continue using Econazole 1% after my symptoms clear up?

The official product information specifies that the full prescribed course, which typically lasts two to four weeks depending on the condition, is required to be completed. This measure is intended to help reduce the possibility of the infection returning after treatment has ended.

Q: What happens if I stop using Econazole 1% before the recommended treatment duration?

Official procedural protocol states that the full course duration is required to be completed. Stopping the treatment early is discouraged because it may increase the possibility of the infection returning (recurrence).

Q: Can using too much Econazole 1% cause health issues?

Regulatory information addresses risks associated with exceeding the prescribed amount, noting that applying the medication to a large body surface area, under occlusion (covering with a bandage), or to the genital area can potentially increase the amount absorbed into the body (systemic absorption).

Q: Are there ingredients in Econazole 1% formulations known to cause irritation?

Econazole 1% cream contains several inactive ingredients, such as mineral oil and propylene glycol. If a user experiences a reaction that suggests chemical irritation or sensitivity, regulatory guidelines describe discontinuing the medication in these cases.

Q: Is it possible for the fungal infection to return after a course of Econazole 1% treatment?

Yes, official documents state that the full treatment course is required to be completed in order to reduce the possibility of recurrence. Completing the full course of treatment is intended to minimize the chance of the infection returning.

Q: Does Econazole 1% lose effectiveness over time or after the tube is opened?

Official storage requirements state that the container is required to be kept tightly closed and stored at a specific temperature. The medication is also required to be discarded after the printed expiration date has passed to maintain its labeled stability.

Q: Can Econazole 1% be used for conditions that are not fungal infections?

Econazole is specifically classified as an antifungal agent and is indicated only for treating fungal or yeast infections of the skin. Regulatory information states that the medicine will not treat infections caused by bacteria or viruses.

Q: What is the expected outcome if Econazole 1% is used correctly?

The expected outcome for Econazole 1% when used correctly is the clinical and mycological clearing of the infection. This means the fungus is cleared, and the patient's symptoms are resolved, often with early symptom relief.

Q: What are the general expectations for a patient starting Econazole 1% treatment?

General expectations for treatment include using the product for a fixed duration (two to four weeks) and experiencing early relief of symptoms. Minor side effects such as burning, itching, or redness at the application site are common and may be experienced.

Q: Does Econazole 1% have any known effects on laboratory blood tests?

Official data indicates that Econazole 1% has extremely low systemic absorption when applied topically to the skin. The label only requires monitoring of INR or prothrombin time in patients who are simultaneously taking oral anticoagulants, due to a documented drug interaction.

Q: Is Econazole 1% safe to use on cracked or broken skin?

The product label advises caution regarding application to a large body surface area as this increases the risk of systemic absorption. For this reason, some product warnings may advise against applying the medicine to wounds or damaged skin.

Q: Is Econazole 1% an over-the-counter medicine or does it require a prescription?

Econazole 1% cream and foam are available for use only with a healthcare professional’s prescription. The official label specifies the prescription-only status (Rx only).

Q: Why does the packaging for Econazole 1% emphasize personal hygiene?

Patient counseling information often includes recommendations for hygiene measures to help clear the infection and prevent its return. These measures can involve thoroughly drying the affected area, wearing clean cotton socks, and using ventilated shoes.

Q: How should the area be cleaned before applying Econazole 1%?

Procedural guidance often provided in patient counseling information states that the affected area of the skin is to be cleaned and patted dry before the medicine is applied.

Q: Is it appropriate to use Econazole 1% for general skin irritation?

Econazole 1% is specifically indicated only for treating fungal or yeast infections of the skin. It is not indicated for treating general skin irritation that is not caused by a susceptible fungus.

How should Econazole 1% be stored and disposed of?

How to Store and Dispose of Econazole 1%

Storage of Econazole 1% (cream and foam) must adhere to official regulatory requirements to maintain its labeled stability.

Storage Conditions

Requirement	Details
Temperature	Store at 20 C to 25 C (68 F to 77 F). Do not freeze and avoid storage above 25 C.
Protection	Keep the container tightly closed and store in a dry place, out of the reach of children.
Foam Handling	The topical foam is flammable; do not expose to heat, direct sunlight, or temperatures above 49 C (120 F). Do not puncture or incinerate the container.